Lv2
198 积分 2023-08-03 加入
Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu corrected intercept method’ (FCIM)
8天前
已完结
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
25天前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview
30天前
已完结
Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
30天前
已完结
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
1个月前
已完结
Strategies for successful dose optimization in oncology drug development: a practical guide
3个月前
已完结
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
3个月前
已完结
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
4个月前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
4个月前
已完结
Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma
5个月前
已关闭
皖公网安备34019202002308
